Dosing & Uses
Dosage Forms & Strengths
tablet
- 10mg (elemental)
- 15mg (elemental)
- 93mg (aspartate; 25mg elemental)
- 50mg (gluconate; 5.7mg elemental)
capsule
- 16.67mg
injectable solution
- 0.1mg/mL
Adequate Intake
Male: 1.9-2.3 mg/day
Female: 1.6-1.8 mg/day
Pregnancy: 2 mg/day
Lactation: 2.6 mg/day
Prevention of Deficiency
Parenteral solution (TPN):150-800 mcg/day IV
Osteoporosis (Off-label)
5 mg PO qDay
Dosage Forms & Strengths
injectable solution: MnCl2
- 0.1mg/mL
Adequate Intake
<6 months: 0.3-0.6 mg/day
6-12 months: 0.6-1.0 mg/day
1-3 years: 1.0-1.5 mg/day
3-8 years: 1.5-2.0 mg/day
8-13 years: 1.9 mg/day (males); 1.6 mg/day (females)
13-18 years: 2.2 mg/day (males); 1.6 mg/day (females)
Prevention of Deficiency
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (1)
- baloxavir marboxil
manganese will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.
Monitor Closely (3)
- delafloxacin
manganese will decrease the level or effect of delafloxacin by cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents.
- omadacycline
manganese will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- sarecycline
manganese will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
Minor (14)
- calcium acetate
calcium acetate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.
- calcium carbonate
calcium carbonate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.
- calcium chloride
calcium chloride, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.
- calcium citrate
calcium citrate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.
- calcium gluconate
calcium gluconate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.
- carbonyl iron
carbonyl iron decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferric maltol
ferric maltol decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous fumarate
ferrous fumarate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous gluconate
ferrous gluconate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous sulfate
ferrous sulfate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- iron dextran complex
iron dextran complex decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- iron sucrose
iron sucrose decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- polysaccharide iron
polysaccharide iron decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- rose hips
rose hips decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
Not well documented
Warnings
Contraindications
Direct IV/IM injection administration (must dilute)
Cautions
May cause tissue damage if administered IV or IM directly due to very acidic solution (pH 2.0)
Injection contains aluminum; use caution in renal impairment and premature infants
Use caution in liver/biliary tract dysfunction, renal impairment (may need to decrease or withhold dose)
Pregnancy & Lactation
Pregnancy Category: inj: C
Lactation: Use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Nutrition
Sources
Pineapples, almonds, oatmeal, chocolate, pumpkin seeds, whole wheat pasta, pecans, spinach
Pharmacology
Mechanism of Action
Cofactor in many enzymes, incl superoxide dismutase (SOD, an antioxidant)
Necessary for glycemic control, energy metabolism, thyroid hormone function
May enhance bone turnover, cartilage synthesis
Pharmacokinetics
Absorption: Poor
Distribution: Mitochondria of kidney, liver, pituitary gland, and bone
Excretion: Bile (primarily); urine (negligible)
Administration
IV Info
Dilute in at least 100 mL (do NOT use undiluted)
Use promptly after mixing & in a single operation
No preservatives-discard unused portion
